PROCEPT BioRobotics (PRCT) EBIT (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of EBIT data on file, last reported at -$32.6 million in Q1 2026.

• On a quarterly basis, EBIT fell 18.84% year-over-year to -$32.6 million in Q1 2026; TTM through Mar 2026 was -$109.0 million, a 13.1% decrease from a year earlier, with the FY2025 full-year figure at -$103.9 million, down 7.5% from the prior year.
• EBIT for Q1 2026 stood at -$32.6 million, down from -$31.0 million in the prior quarter.
• Over the last five years, EBIT for PRCT reached as high as -$15.7 million in Q1 2022 and fell as low as -$32.6 million in Q1 2026.
• Historically, EBIT has averaged -$24.9 million across 5 years, with a median of -$25.6 million in 2023.
• Across the five-year window, EBIT sank 80.7% in 2023 and soared 33.32% in 2024, its largest moves.
• Year by year, EBIT stood at -$25.0 million in 2022, then dropped by 18.04% to -$29.6 million in 2023, then surged by 33.32% to -$19.7 million in 2024, then sank by 57.49% to -$31.0 million in 2025, then dropped by 5.04% to -$32.6 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$32.6 million in Q1 2026, -$31.0 million in Q4 2025, and -$23.2 million in Q3 2025.